SYK vs BSX — Key Metrics
| Metric | SYK (STRYKER CORP) | BSX (BOSTON SCIENTIFIC CORP) |
|---|---|---|
| Price | 318.15 | 43.64 |
| Market Cap | 121.12 Billion | 63.26 Billion |
| P/E (TTM) | 33.63 | 18.34 |
| P/B (Quarterly) | 4.737 | 2.506 |
| P/S (TTM) | 4.61 | 3.0 |
| Net Profit Margin (TTM) | 13.8 | 16.6 |
| Gross Margin (TTM) | 65.3 | 69.1 |
| ROE (TTM) | 15.6 | 13.9 |
| Revenue Growth YoY (TTM) | n/a | n/a |
Upfront Investment - S&P 500 Stock Comparison & AI Analysis
AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.
Performance Comparison
AI Model Recommendation
Greatly Underperform
Greatly Outperform
Recommendation Summary
Stock SYK is projected to greatly underperform the market, stock BSX is projected to greatly outperform the market. Upfront Recommendation: BSX.
Financial Metrics
| SYK | Metrics | BSX |
|---|---|---|
| $318.15 | Price | $43.64 |
| — | Market Capitalization | — |
| 33.63 | Price to Earnings Ratio | 18.34 |
| 4.61 | Price to Sales | 3.0 |
| 26.49 | Price to FCF Ratio | 18.99 |
| 7.05 | Price to Gross Profit | 4.34 |
| 72.05 | Price to R&D | 29.3 |
| 8.54 | Price to Current Assets | 7.75 |
SYK vs BSX at a glance
Stryker Corp (SYK) and Boston Scientific Corp (BSX) are both Medical Devices companies in the Healthcare sector. SYK is the larger, at $121.1 billion in market value against $63.3 billion for BSX, about 1.9 times the size.
On trailing-twelve-month figures, SYK trades at 33.6 times trailing earnings and BSX at 18.3; net profit margins are 13.8% and 16.6%.
The Upfront Investment model currently rates SYK Greatly Underperform and BSX Greatly Outperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.